AstraZeneca
AstraZeneca’s Oral PCSK9 Inhibitor AZD0780 Demonstrates Significant LDL-C Reduction in Phase 1 Trial
PCSK9 inhibitor, AZD0780, AstraZeneca, cholesterol reduction, phase 1 trial, statin therapy, hypercholesterolemia, cardiovascular disease
AstraZeneca and Daiichi Sankyo’s TROP2 ADC Demonstrates Clinically Meaningful Survival Improvement in Phase 3 Lung Cancer Subgroup
AstraZeneca, Daiichi Sankyo, TROP2 ADC, Datopotamab Deruxtecan, Lung Cancer, Phase 3 Trial, Survival Improvement, Nonsquamous Non-Small Cell Lung Cancer
AstraZeneca Acquires Option for SixPeaks: A Potential Breakthrough in Obesity Biotechnology
AstraZeneca, SixPeaks, Versant Ventures, obesity, biotechnology, acquisition, option, breakthrough.
AstraZeneca’s Billion-Dollar Bet: Accelerating Biopharma Innovation in China
AstraZeneca, China sales, biopharma innovation, investment, research and development, healthcare market, pharmaceutical industry, clinical trials, partnerships, collaborations.
AstraZeneca Invests $1.5 Billion in Singapore for Comprehensive Antibody-Drug Conjugate Manufacturing
AstraZeneca, Singapore, antibody-drug conjugate (ADC), manufacturing, investment, biotechnology, pharmaceuticals, end-to-end production, cancer treatment.
AstraZeneca’s Ambitious Vision: Pursuing $80 Billion in Revenue and 20 New Drugs by 2030
AstraZeneca, revenue target, new drugs, 2030, growth strategy, pharmaceutical industry, healthcare innovation, biotechnology, drug development, market expansion.
AstraZeneca Targets $80 Billion in Revenue by 2030: A Rapid Growth Trajectory
AstraZeneca, revenue target, 2030, growth trajectory, pharmaceutical industry, drug development, healthcare solutions.
Tezspire Clinical Trials by AstraZeneca and Amgen: Empowering Patient Choice in COPD Treatment
Tezspire, AstraZeneca, Amgen, clinical trials, COPD, patient choice, pivotal studies, treatment.
AstraZeneca Ordered to Pay Pfizer Over $107 Million in Tagrisso Patent Infringement Case
AstraZeneca, Pfizer, Tagrisso, patent infringement, jury verdict, damages, lung cancer treatment
AstraZeneca Invests $1.5 Billion in Singapore for State-of-the-art Antibody-Drug Conjugate Manufacturing Facility
AstraZeneca, Singapore, investment, antibody-drug conjugate (ADC), manufacturing facility, end-to-end production, biotechnology, pharmaceuticals, cancer treatment, innovation, global expansion.